Cyclin D1 expression by IHC (encoded by CCND1)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CCND1-IHC |
|---|---|
| Type | Biomarker |
| Aliases | BCL1CCND1Cyclin D1Cyclin D1 expressionЕкспресія Cyclin D1 (CCND1) — ІГХ |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 SRC-NCCN-MM-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC on FFPE biopsy (anti-cyclin D1 antibody, SP4 clone) Unitscategorical (positive ≥10% nuclear staining | negative) |
| Related biomarkers | BIO-T11-14-IGH-CCND1 BIO-CD5-IHC |
Notes
Cross-disease relevance: - **MCL** (defining ~95%): nuclear cyclin D1 over-expression from t(11;14)(q13;q32) IGH/CCND1 translocation. Cyclin D1-negative MCL (~5%) requires SOX11 + clinical context for diagnosis. - **MM** (~15-20%): t(11;14) IGH/CCND1 subset — venetoclax-sensitive population (BELLINI trial signal); emerging targeted therapy. - **HCL** subset: cyclin D1-positive. Distinguishes from CLL. - **Plasma cell myeloma cyclin D1+ subset**: t(11;14) defines this subgroup — favorable cytogenetic + venetoclax-responsive. Drive r/r venetoclax pathway across MCL + MM t(11;14) subsets — future scope.
Used By
Actionability
BMA-CCND1-IHC-MCL- Cyclin D1 IHC is a defining diagnostic marker of MCL (positive in >95%; SOX11 used in cyc...BMA-CCND1-IHC-MM- CCND1 (cyclin D1) overexpression in MM strongly correlates with t(11;14) and BCL2 depende...
Biomarker
BIO-CD23-IHC- CD23 expression by IHC / flow cytometryBIO-CD5-IHC- CD5 expression by IHC / flow cytometryBIO-T11-14-IGH-CCND1- t(11;14)(q13;q32) IGH/CCND1 by FISH
Indications
IND-MCL-1L-BTKI-R- IND-MCL-1L-BTKI-RIND-MCL-1L-INTENSIVE- IND-MCL-1L-INTENSIVEIND-MCL-2L-ACALABRUTINIB- IND-MCL-2L-ACALABRUTINIB
Questionnaires
QUEST-MCL-1L-STUB- Mantle Cell Lymphoma — first line